Fireman B.V. (IFRX) Stock Price, Quote & News

Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa,...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 3641 508 180

Website: www.inflarx.de

Address:

Winzerlaer Str. 2, Jena, Germany

jerzypawlik Feb. 23 at 11:56 PM

$IFRX Patience always prevail. Sometimes take very long time, but reward is colossal.

1 · Reply

trailblazerman9 Feb. 23 at 4:53 PM

$IFRX 2025 Full year financials will be released in mid-March. It will be interesting to see how much cash they report left as of 12/31/25 and number of employees. It will be interesting to see how much of the 73m ATM they have left as well.

2 · Reply

MrCompassion Feb. 23 at 3:17 PM

$IFRX Revelation of the obvious… “Current immunomodulatory strategies for HS and other neutrophilic inflammatory disorders have largely repurposed biologics such as IL-17 inhibitors, that target adaptive immunity. Despite neutrophils being among the most abundant cell type in HS lesions, they remain an underexplored therapeutic target partly due to limited understanding of their complex biology compared with other immune components. Novel approaches that selectively target neutrophil functions such as chemotaxis, neutrophil serine protease activity and NET formation, offer the potential to reduce HS-related inflammation while preserving broader immune competence. Given the central role of neutrophils in pus formation, such strategies may also alleviate the pain, drainage and odor which constitute a major component of the symptom burden for individuals living with HS.” Published today: https://www.mdpi.com/1422-0067/27/4/2076 Onwards to 7000 pubs.

2 · Reply

maineamerica Feb. 23 at 3:04 PM

$IFRX eyeing this again

1 · Reply

JerzeyDevil Feb. 23 at 3:03 PM

$IFRX What’s the plan here? Like are we going to wait another six years to do anything that benefits shareholders? Such a joke.

0 · Reply

MrCompassion Feb. 23 at 2:54 PM

$IFRX A “cash runway to mid-2027” is nothing to brag about, especially considering that InflaRx isn’t currently directly managing any study. At this dismal mcap, the only logical conclusion is that a price-moving catalyst is pending. What could it be? An FDA-accepted HS p2b design that obviously will measure tunnel reduction along with appropriate dosing? No! Funding or statistically significant – and market competitive – data is all the market values with this beat up ticker about fail after fail after fail; the best biotech that never is. So then what to expect? Some kind of partnership or licensing announcement is all that’s left to sell. This week? Next? InflaRx hints good things before summer arrives. So let’s see some success for a change.

0 · Reply

cielo1 Feb. 22 at 9:17 PM

$IFRX Could a large firm buy all the shares everyday and then vote no on all mgtms items until they are forced to sell? Would take a while but worth it at this juncture $60M is pocket change for even a medium sized firm. Salvaging vilo for severe HS and PG is still totally worth $1B in capable hands with resources!

1 · Reply

trailblazerman9 Feb. 22 at 2:30 PM

$IFRX I think we will see news from Inflarx this week. 🤞🤞

4 · Reply

cielo1 Feb. 22 at 8:01 AM

$IFRX Massive inflamation due to spike protein izicopan now! Major new scientific papers finally in the domain! https://youtu.be/GEmJGuIsDkw?si=gn9d71s2XxHRlsBk

1 · Reply

jerzypawlik Feb. 21 at 10:55 PM

$IFRX I don't see this going down from here. I'm actually expecting to go over $1. this week. Let's get it done bulls.

2 · Reply

InflaRx Announces Participation in February Investor Conferences

Jan 8, 2026, 8:00 AM EST - 6 weeks ago

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

Dec 30, 2025, 7:30 AM EST - 7 weeks ago

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

Dec 11, 2025, 7:30 AM EST - 2 months ago

InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904

Nov 10, 2025, 2:41 PM EST - 3 months ago

InflaRx N.V. (IFRX) Discusses Topline Phase 2a Data in Chronic Spontaneous Urticaria and Hidradenitis Suppurativa Transcript

Nov 10, 2025, 7:30 AM EST - 3 months ago

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)

Nov 7, 2025, 4:05 PM EST - 3 months ago

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria

Oct 21, 2025, 7:20 AM EDT - 4 months ago

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Sep 12, 2025, 8:30 AM EDT - 5 months ago

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aug 21, 2025, 7:30 AM EDT - 6 months ago

InflaRx Announces Participation in September Investor Conferences

Aug 7, 2025, 7:30 AM EDT - 7 months ago

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 7:30 AM EDT - 7 months ago

InflaRx to Report Second Quarter 2025 Results on August 7, 2025

Jul 11, 2025, 4:15 PM EDT - 8 months ago

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

May 28, 2025, 11:00 AM EDT - 9 months ago

InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease

May 28, 2025, 1:30 AM EDT - 9 months ago

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

May 22, 2025, 7:30 AM EDT - 9 months ago

InflaRx to Participate in Upcoming Investor Conferences

May 7, 2025, 7:30 AM EDT - 10 months ago

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 30, 2025, 7:30 AM EDT - 10 months ago

InflaRx to Report First Quarter 2025 Results on May 7, 2025

Mar 20, 2025, 7:30 AM EDT - 1 year ago

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

Mar 7, 2025, 8:00 AM EST - 1 year ago

InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Feb 28, 2025, 9:00 AM EST - 1 year ago

InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Feb 25, 2025, 7:30 AM EST - 1 year ago

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

Feb 18, 2025, 4:01 PM EST - 1 year ago

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2025, 9:45 PM EST - 1 year ago

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2025, 4:01 PM EST - 1 year ago

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

Jan 23, 2025, 7:30 AM EST - 1 year ago

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

Jan 15, 2025, 12:30 PM EST - 1 year ago

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

Dec 20, 2024, 7:30 AM EST - 1 year ago

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

Nov 15, 2024, 7:51 AM EST - 1 year ago

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Nov 8, 2024, 7:30 AM EST - 1 year ago

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 25, 2024, 7:30 AM EDT - 1 year ago

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

Sep 3, 2024, 7:30 AM EDT - 1 year ago

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

Aug 27, 2024, 7:30 AM EDT - 1 year ago

InflaRx Announces Participation in September Investor Events

Aug 8, 2024, 7:30 AM EDT - 1 year ago

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

Jun 24, 2024, 8:02 AM EDT - 1 year ago

InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

Jun 5, 2024, 12:00 PM EDT - 1 year ago

InflaRx Hosts R&D Event Highlighting the Promise of INF904

May 21, 2024, 2:30 PM EDT - 1 year ago

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

May 8, 2024, 7:30 AM EDT - 1 year ago

InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 24, 2024, 7:30 AM EDT - 1 year ago

InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event

Mar 21, 2024, 7:00 AM EDT - 2 years ago

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

Mar 19, 2024, 7:30 AM EDT - 2 years ago

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

Feb 22, 2024, 7:30 AM EST - 2 years ago

InflaRx Appoints Jan Medina as Head of Investor Relations

Jan 25, 2024, 7:30 AM EST - 2 years ago

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

Jan 4, 2024, 7:00 AM EST - 2 years ago

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

Nov 6, 2023, 7:30 AM EST - 2 years ago

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

Nov 1, 2023, 7:30 AM EDT - 2 years ago

InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

Sep 11, 2023, 7:00 AM EDT - 2 years ago

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

Sep 6, 2023, 5:31 PM EDT - 2 years ago

InflaRx: Small German Company Targeting A Rare Indication

Aug 30, 2023, 7:30 AM EDT - 2 years ago

InflaRx's Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)

jerzypawlik Feb. 23 at 11:56 PM

$IFRX Patience always prevail. Sometimes take very long time, but reward is colossal.

1 · Reply

trailblazerman9 Feb. 23 at 4:53 PM

2 · Reply

MrCompassion Feb. 23 at 3:17 PM

2 · Reply

maineamerica Feb. 23 at 3:04 PM

$IFRX eyeing this again

1 · Reply

JerzeyDevil Feb. 23 at 3:03 PM

$IFRX What’s the plan here? Like are we going to wait another six years to do anything that benefits shareholders? Such a joke.

0 · Reply

MrCompassion Feb. 23 at 2:54 PM

0 · Reply

cielo1 Feb. 22 at 9:17 PM

1 · Reply

trailblazerman9 Feb. 22 at 2:30 PM

$IFRX I think we will see news from Inflarx this week. 🤞🤞

4 · Reply

cielo1 Feb. 22 at 8:01 AM

$IFRX Massive inflamation due to spike protein izicopan now! Major new scientific papers finally in the domain! https://youtu.be/GEmJGuIsDkw?si=gn9d71s2XxHRlsBk

1 · Reply

jerzypawlik Feb. 21 at 10:55 PM

$IFRX I don't see this going down from here. I'm actually expecting to go over $1. this week. Let's get it done bulls.

2 · Reply

trailblazerman9 Feb. 20 at 9:52 PM

$IFRX While both RA Capital and Adage left, a number of new big institutional buys came in as seen in the latest filings. Let‘s give some due credit to Jan Medina from IR for that - because IMO we would be trading much lower without his efforts.

1 · Reply

morgueana Feb. 20 at 4:53 PM

$IFRX Well, we now see that RA Capital is no longer a shareholder. I am left to wonder if they sold slowly over time or did they dump all at once into the p2a data release of HS and CSU. Even worse, did they play Jan and Niels to do an unprecedented Friday afternoon preannouncement of the data release date in order to sell into a rally and even to short the data release, knowing there would be a drought of price moving catalysts moving forward. I have never forgiven investor relations for that Friday press release blunder, but I guess this is all part of the biotech investment game and RA and Adage-like firms control the movement of stocks--sometimes for the better for shareholders but most times for the worse.

3 · Reply

FlowerInTheCellar Feb. 20 at 4:08 PM

$IFRX https://event.summitcast.com/view/CTtthLh2Bi2D9aYoKpvtEv/guest_book?session_id=ZXpMpA4QabmsoEeQb8GgCH Well, it's almost here! Oppenheimer 36th Annual Healthcare Life Sciences Conference I've posted the registration link and the US time with the corresponding German time (because I'm from Germany 👍🏻). Original: 📅 February 25, 2026 🕗 8:40 AM ET ➡️ Germany: 📅 February 25, 2026 🕑 2:40 PM (2:40 PM CET)

1 · Reply

levystrauss Feb. 20 at 3:13 PM

$IFRX .....

1 · Reply

MrCompassion Feb. 19 at 4:17 PM

$IFRX Vilo-ARDS: Mayo Clinic was added back in Sept 2025, now Cleveland Clinic has recently been added. Not sure of the value anymore but nice to see anti-C5a biotech make its way into ICUs of the top two best hospitals in the world. Hyperactive neutrophils don’t stand a chance. https://clinicaltrials.gov/study/NCT06701682 https://rankings.newsweek.com/worlds-best-hospitals-2025 Vilo licensing anyone?

1 · Reply

Capitalbrother Feb. 18 at 4:49 PM

$IFRX I’ve recently added several stocks to the portfolio. Now we’re hoping for positive, forward-looking developments — the rebound will come.

1 · Reply

OfficialStocktwitsUser Feb. 18 at 4:34 PM

$IFRX RSI: 46.85, MACD: -0.0487 Vol: 0.06, MA20: 0.90, MA50: 1.00 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

MrCompassion Feb. 18 at 4:31 PM

$IFRX ABVX just passed $10B mcap, primarily based on the success of a p3 study in UC using their once a day oral, obefazimod – impressive for a small biotech out of France, founded in 2013. Another drug that games the immune system (vs fixing what’s broken), this one toying with intracellular signaling to artificially boost cytokine dampening, primarily affecting TNF, IL-6, and IL-17 production. Considering that hyperactive neutrophils are the primary drivers of tissue damage in UC, amplifying epithelial injury and sustaining the dreaded feedback loop as seen in many other diseases, wouldn’t it be great if there was a drug that actually fixes what’s broken: hyperactive neutrophils. Another small non-US based biotech, InflaRx, was founded in 2007. Going after UC such a risk? $10B vs $0.06B. Nonsense. https://finviz.com/quote.ashx?t=ABVX&ty=c&ta=1&p=m https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.70056

1 · Reply

trailblazerman9 Feb. 18 at 1:19 PM

$IFRX Now 28.5% institutional ownership, so it is lower now. Disappointed RA Capital sold 2m shares after just coming back from IPO days. Adage also sold all 331k shares after a brief return. Guess they don't believe Inflarx can turn around. :-( Fortunately others added or it would be much worse.

1 · Reply

mconnell Feb. 18 at 2:45 AM

$IFRX Ra sold its position in full Gulp

4 · Reply

MrCompassion Feb. 17 at 6:38 PM

$IFRX Another ‘hyperactive neutrophils are bad’ paper: https://link.springer.com/article/10.1007/s00011-025-02157-7 Part of the paper’s funding from Precision Medicine in Chronic Inflammation (PMI), itself funded by the “Joint Science Conference of the Federal and State Governments, together with the German Research Foundation and the German Council of Science and Humanities.” https://www.precisionmedicine.de/en/ PMI believes that “fundamental research results should be transferred as quickly as possible from bench to bedside.” There’s talk about “precision medicine in chronic inflammation,” hopefully in regards to a system shared amongst billions of hosts. Considering that the most prescribed drugs in the world are about controlling LDL cholesterol and glucose levels in blood – a global problem, not host specific – system precision is the practical choice. To that, C5a signaling has been around for ~500m years: seems important as to precision medicine when thinking about inflammation and what constitutes healthy blood.

1 · Reply

theBigDollarski Feb. 17 at 5:17 PM

$IFRX POS

0 · Reply

Market Cap	60.06M
Revenue (ttm)	180,000.00
Net Income (ttm)	-49.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-27,694.44%
Debt to Equity Ratio	0.00

Volume	206,800
Avg Vol	547,156
Day's Range	N/A - N/A
Shares Out	67.13M
Stochastic %K	73%
Beta	1.46
Analysts	Strong Sell
Price Target	$10.29